Return to study ST000492 main page
MB Sample ID: SA025552
Local Sample ID: | ms5687-31 |
Subject ID: | SU000513 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Subject:
Subject ID: | SU000513 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Species Group: | Human |
Factors:
Local Sample ID | MB Sample ID | Factor Level ID | Level Value | Factor Name |
---|---|---|---|---|
ms5687-31 | SA025552 | FL006087 | sleep apnea | Disease |
Collection:
Collection ID: | CO000507 |
Collection Summary: | For the metabolic markers, 9 ml blood will be drawn into 3 EDTA tubes (3 ml each) and gently centrifuged at 4°C for 10 min; plasma aliquots were immediately frozen and stored at -80 °C; will be stored at -80ºC in the CTRC until all samples are collected and then sent to Mayo Clinic Metabolomics Core via LC-MS/MS for simultaneous detection and quantification of metabolites for analyses. |
Sample Type: | Blood |
Treatment:
Treatment ID: | TR000527 |
Treatment Summary: | Recruitment of subjects will take place from the clinic population in collaboration with the Penn Sleep Center. Patients newly diagnosed with OSA will be solicited for via an overnight sleep study, which is general monitoring of sleep and variety of body functions during sleep. This includes brain (EEG), eye (EOG), and muscle activity and heart rhythm. The diagnosis of OSA will be established by full sleep study. First, the PI will screen for eligibility and obtain informed consent. We will assess height, weight, medical history, demographics. EDS will be measured subjectively on the night of enrollment in the study and determined using the Epworth Sleepiness Scale. The information regarding gender, BMI, smoking, age, medications (name/duration/frequency), and presence of comorbidities (e.g. hypertension, CVD defined by doctor diagnosis of myocardial infarction, stroke, or heart failure) will then be obtained via the electronic medical record. We will also ask subjects whether they exercise by asking participants the yes/no question: “During the past month, did you participate in any physical activities or exercises?” Second, the subject will undergo diagnostic PSG and we will enforce fasting prior to bedtime. Third, biological samples will be collected in the morning after the sleep study. Patients who have agreed to participate will undergo a blood draw (20 ml) and urine collection (30 ml) on the morning after PSG. Laboratory analysis of the biological samples will be conducted in collaboration with the Clinical Translation Research Center (CTRC). Finally, subjects will have 1 or 2 practice sessions with the PVT prior to administration of the task. PVT test will be conducted 3 times, at approximately 10:00, 12:00, and 14:00 and automatically scored. This will be done on the day after the sleep study. |
Sample Preparation:
Sampleprep ID: | SP000520 |
Sampleprep Summary: | ceramide concentrations |
Combined analysis:
Analysis ID | AN000758 |
---|---|
Analysis type | MS |
Chromatography type | HILIC |
Chromatography system | Waters Acquity |
Column | AMT HALO HILIC 2 (150 x 4.6mm,2.7um) |
MS Type | ESI |
MS instrument type | Triple quadrupole |
MS instrument name | Thermo Quantiva QQQ |
Ion Mode | POSITIVE |
Units | micromolar |
Chromatography:
Chromatography ID: | CH000544 |
Instrument Name: | Waters Acquity |
Column Name: | AMT HALO HILIC 2 (150 x 4.6mm,2.7um) |
Chromatography Type: | HILIC |
MS:
MS ID: | MS000670 |
Analysis ID: | AN000758 |
Instrument Name: | Thermo Quantiva QQQ |
Instrument Type: | Triple quadrupole |
MS Type: | ESI |
Ion Mode: | POSITIVE |